- Home
- BHC vs NNNN Comparison
BHC vs NNNN Comparison
Compare BHC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- NNNN
- Stock Information
- Founded
- BHC N/A
- NNNN 2021
- Country
- BHC Canada
- NNNN Germany
- Employees
- BHC N/A
- NNNN N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BHC Health Care
- NNNN Health Care
- Exchange
- BHC Nasdaq
- NNNN Nasdaq
- Market Cap
- BHC 2.4B
- NNNN 2.2B
- IPO Year
- BHC N/A
- NNNN 2025
- Fundamental
- Price
- BHC $6.38
- NNNN $28.84
- Analyst Decision
- BHC Hold
- NNNN
- Analyst Count
- BHC 2
- NNNN 0
- Target Price
- BHC $9.00
- NNNN N/A
- AVG Volume (30 Days)
- BHC 1.7M
- NNNN 73.9K
- Earning Date
- BHC 10-29-2025
- NNNN 10-23-2025
- Dividend Yield
- BHC N/A
- NNNN N/A
- EPS Growth
- BHC N/A
- NNNN N/A
- EPS
- BHC 0.27
- NNNN 0.06
- Revenue
- BHC $9,858,000,000.00
- NNNN $8,185,146.00
- Revenue This Year
- BHC $6.28
- NNNN N/A
- Revenue Next Year
- BHC $3.76
- NNNN N/A
- P/E Ratio
- BHC $24.09
- NNNN $545.12
- Revenue Growth
- BHC 7.13
- NNNN 21.95
- 52 Week Low
- BHC $4.25
- NNNN $5.18
- 52 Week High
- BHC $9.85
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- BHC 38.57
- NNNN 35.78
- Support Level
- BHC $6.40
- NNNN $22.08
- Resistance Level
- BHC $6.81
- NNNN $51.33
- Average True Range (ATR)
- BHC 0.18
- NNNN 5.72
- MACD
- BHC -0.02
- NNNN -0.91
- Stochastic Oscillator
- BHC 5.00
- NNNN 21.32
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.